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We report the first known case of a device-related
bloodstream infection involving Staphylococcus lugdunen-
sis small-colony variants. Recurrent pacemaker-related
bloodstream infection within a period of 10 months illus-
trates the poor clinical and microbiologic response even to
prolonged antimicrobial drug therapy in a patient infected
with this staphylococcal subpopulation.
D
uring the past decade, Staphylococcus lugdunensis
has emerged as an important pathogen implicated in
both community-acquired and nosocomial infections (1,2).
Clinical manifestations of infections with these organisms
include abscesses (3), meningitis (4), ventriculoperitoneal
shunt infection (5), spondylodiscitis (6), prosthetic joint
infection (7), catheter-related bacteremia (2), and endo-
carditis (1). Infections with S. lugdunensis tend to have a
more fulminant course, with an outcome resembling that
of S. aureus infections rather than that caused by coagu-
lase-negative staphylococci (8). In addition, these organ-
isms are frequently misidentified as S. aureus because of
their morphologic appearance with yellow pigmentation
and complete hemolysis when cultured on blood agar.
Small-colony variants (SCVs) are mainly reported in S.
aureus, and interest in infections with SCVs has recently
increased after an association between recovery of S.
aureus SCVs and persistent and relapsing infection has
become evident (9). SCVs are a slow-growing subpopula-
tion of the species with characteristics that can associated
by a common factor, i.e., alterations in electron transport
(10). The generation time for SCVs is up to 9-fold longer
than for metabolically normal strains, which results in tiny
colonies that are frequently not visible until after 48 to 72
hours of incubation. Consequently, correct identification
and susceptibility testing for clinical laboratories are com-
plicated, which may result in diagnostic underestimation
and therapeutic failures. While most studies have dealt
with SCVs of S. aureus, little is known about infections
with SCVs of coagulase-negative staphylococci. Recently,
2 cases of bloodstream infections caused by SCVs of S.
epidermidis and  S. capitis, respectively, were reported
(11). Both infections were related to foreign bodies and
observed after pacemaker implantation. 
We report the first known case of a device-related blood-
stream infection due to S. lugdunensis SCVs and other
colony variants of this species. Of particular interest, this
infection was also observed after pacemaker implantation. 
The Case
In July 2003, a 61-year-old man was transferred from a
local hospital to our cardiothoracic surgery department
with a diagnosis of pacemaker lead infection. Past medical
history included nephrectomy in 1996 for cancer of the left
kidney and implantation of a universal demand pacemaker
(dual chamber pacemaker) for treatment of sick sinus syn-
drome in 1990. In August 2002, after being in place for 12
years, the pacemaker battery was replaced. Three months
later, the patient was admitted to a local hospital with a
temperature of 40°C and chills. Laboratory findings
included a leukocyte count of 17,500/µL and a C-reactive
protein (CRP) level of 90 mg/L. A transesophageal
echocardiogram showed thickening of the left coronary
aortic valve, and thrombotic material was seen on the ven-
tricular pacemaker lead. A blood culture drawn on admis-
sion showed S. lugdunensis susceptible by agar diffusion
to penicillin, oxacillin, erythromycin, clindamycin,
rifampin, and aminoglycosides. Antimicrobial drug thera-
py was instituted with intravenous ampicillin/sulbactam
and gentamicin for 14 days with prompt resolution of clin-
ical symptoms, and follow-up blood cultures remained
negative. Three days later, however, a spiking fever and
chills developed in the patient. Antimicrobial drug treat-
ment was changed to intravenous vancomycin and
rifampin. The patient’s condition improved rapidly, and he
was discharged after 3 weeks of antimicrobial drug thera-
py when the CRP value had returned to normal. 
Two months later in February 2003, the patient was
readmitted to the cardiology department with the presump-
tive diagnosis of endocarditis. During a transient febrile
episode, a blood culture was obtained that again yielded S.
lugdunensis (Figure 1A). Antimicrobial drug therapy was
resumed with intravenous flucloxacillin and gentamicin.
All 4 follow-up blood cultures obtained 3 and 4 days later,
when the patient was afebrile, were again positive for S.
lugdunensis. An echocardiogram did not show vegetations
or other evidence of endocarditis. Pacemaker removal was
strongly suggested, but the patient refused. After 14 days
of intravenous treatment, the antimicrobial drug regimen
was changed to oral administration of flucloxacillin for 14
days. After a full recovery, the patient was discharged, but
removal of the pacemaker system was recommended if
clinical symptoms reappeared.
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local hospital with recurrent high fever and chills, a leuko-
cyte count of 12,200/µL, and a CRP value of 37 mg/L, but
he did not show any peripheral sign of endocarditis. Four
sets of blood cultures drawn on admission showed S. lug-
dunensis. Atransesophageal echocardiogram showed large
vegetations in the right atrium inserting at the ventricular
lead but no involvement of cardiac valves. The patient
responded promptly to the initiation of antimicrobial drug
therapy with intravenous flucloxacillin and gentamicin and
became afebrile. He was then transferred to our cardiotho-
racic surgery department for pacemaker ablation. 
Four days later, the complete pacemaker system,
including the intracardiac leads, was removed by open
heart surgery. The cardiac valves did not show signs of
infective endocarditis, but large vegetations adhered to
both the atrial and the ventricular lead. Follow-up blood
cultures remained negative but thrombotic material
scraped from the pacemaker leads was analyzed by cul-
ture. After 2 days of incubation, this material yielded non-
hemolytic and nonpigmented, as well as yellow-
pigmented, hemolytic colonies of variable size, which
were gram-positive catalase-positive cocci, consistentwith
staphylococci. The results of subcultures on solid media
suggested a mixed population of staphylococci, with at
least 4 differentcolony morphologies (Figure 1B–E). Four
single-colony subcultures of different colony morphotypes
also produced colony variations that persisted in serialsub-
cultures of single colonies.
Clumping factor was not present and tube coagulase
test results were negative. Identification was initially
attempted with the gram-positive identification card pro-
vided with the VITEK 2 system (bioMérieux, Marcy
l’ Etoile, France). The large hemolytic morphotype
(Figure 1B) showed a profile consistent with S. lugdunen-
sis, with positive results for ornithine decarboxylase, tre-
halose, and L-pyrrolidonyl-β-naphthylamide. Other mor-
photypes were repeatedly identified as S. haemolyticus
(Figure 1C; T index 0.93) and S. auricularis (Figure 1D
and E; T index 0.46), respectively. The S. lugdunensis iso-
late that grew as tiny (pinpoint), nonpigmented, and non-
hemolytic colonies was shown to be a hemin-auxotrophic
SCV (Figure 1E). The S. lugdunensis isolate (large colony
morphotype) was susceptible to all antimicrobial agents in
the VITEK GPS-P526 card test (bioMérieux) and did not
produce β-lactamase. The other morphotypes did not grow
sufficiently to allow antimicrobial susceptibility testing
with the VITEK system. However, susceptibility to peni-
cillin and oxacillin was confirmed by an Etest (AB
Biodisk, Solna, Sweden) for all colony variants.
The API ID 32 Staph system (bioMérieux) identified all
morphotypes as S. lugdunensis, which was later confirmed
by 16S ribosomal RNA gene sequencing using the
RIDOM entries (12). All isolates, including an additional
S. lugdunensis blood isolate obtained in February 2003
that produced flat, white, and nonhemolytic colonies
(Figure 1A), were compared by pulsed-field gel elec-
trophoresis and found to be identical, although the colony
morphology was different (Figure 2).
Postoperative recovery was uneventful. Treatment with
intravenous flucloxacillin and gentamicin was continued
for 14 days. A72-hour electrocardiogram did not show any
need for pacemaker reinsertion. Fourteen days after sur-
gery, the patient was discharged from the hospital, after a
total clinical course of 10 months with recurrent infections.
Conclusions
Previous reports have rarely emphasized colony varia-
tion as an important feature of S. lugdunensis. In the initial
description of the species in 1988 (13), colony variation
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Figure 1. Sheep blood agar plates (A–E) and magnified sectors (a–e) after overnight incubation at 37°C showing different morphotypes
of clonal isolates of the Staphylococcus lugdunensis strain recovered from blood cultures and the infected pocket of a patient with pace-
maker infection. Plates A–D/a–d show S. lugdunensis colonies exhibiting the normal phenotype characterized by colonies of different
diameter, ranging from 0.8 to 2.5 mm with creamy (A/a) or yellow (B–D/b–d) pigmentation and moderately heavy (B/b), weak (C–D/c–d),
or absent (A/a) hemolysis; plate E/e shows the small-colony variant phenotype characterized by tiny (pinpoint), nonpigmented, and non-
hemolytic colonies.was observed in 3 of 11 strains. More recently, Leung et al.
reported colony variation of S. lugdunensis in a fatal case
of endocarditis (14). Unlike other staphylococcal species
such as S. capitis and S. hominis, which show colony vari-
ation that disappeared after extended incubation, mixed
morphotypes of S. lugdunensis were persistently
detectable through incubation and subculture (14). The
authors speculated that preceding antimicrobial drug ther-
apymay play a role in producing colony variation in S. lug-
dunensis and that previous studies may have underreported
the characteristic of colony variationseen in this species. 
Some of the aberrant morphotypes described in earlier
studies may have in fact been SCVs. Both prior exposure
to antimicrobial drugs and the presence of chronic or
recurring infections, often with indwelling foreign devices
that have been associated with SCVs of S. aureus, S. epi-
dermidis, and S. capitis (1,15), are features commonly
observed in infections with S. lugdunensis (2,4,5,7,14). In
our case, repeated courses of gentamicin therapy may
have selected for SCVs. Although the infection showed a
rather benign clinical course and did not confirm other
reports of S. lugdunensis endocarditis in which the infec-
tion was more aggressive, it illustrates the chronic, recur-
rent, and persistent nature of infections with SCVs and the
problems associated with delayed identification of
S. lugdunensis colony variants and interpretation of its
clinical significance. 
The refusal of the patient to have the pacemaker
removed added to the chronic course of the infection.
Although these variants were not identified until removal
of the device, the clinical importance of SCVs for this per-
sistent infection can be anticipated. Clinical isolates are
often a mixed population of parent strains and SCVs.
Because of their different generation times, even a small
percentage of normally growing organisms may rapidly
replace SCVs in liquid medium such as a blood culture
during overnight incubation. Thus, SCVs may have gone
undetected in previously obtained blood cultures.
Increased awareness of colony variation and the possible
occurrence of SCVs as a characteristic feature of S. lug-
dunensis should be helpful in earlier recognition of the
pathogen and appropriate management of the infection.
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